{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:10:40Z","timestamp":1770970240147,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Myelomastocytic leukemia (MML) presenting as a blast phase manifestation of Chronic Myeloid Leukemia (CML) is exceptionally rare, with limited documented cases in the literature. Understanding its distinct clinicopathologic features and treatment outcomes is crucial for optimal patient management. A 45-year-old male with a history of CML since 2016, previously treated with imatinib and dasatinib, presented after treatment interruption with leukocytosis (WBC 27.3\u2009\u00d7\u2009103\/\u03bcL) and 58% circulating blasts showing metachromatic granulation. Bone marrow examination revealed 30% blast cells with strong CD117 and tryptase positivity. Flow cytometry identified two distinct populations: 7% myeloblasts and 27% immature myeloid cells with bright CD117 expression. BCR-ABL1 rearrangement was confirmed with a ratio of 112% (IS). The patient received combination therapy with standard \u201c3\u2009+\u20097\u201d induction chemotherapy and dasatinib. Despite complications of febrile neutropenia, the post-induction bone marrow examination demonstrated achievement of complete morphologic remission. This case highlights the successful initial treatment of myelomastocytic transformation in CML blast phase using intensive combination therapy. The detailed morphologic, immunophenotypic and molecular characterization provides valuable insights into this rare entity, while the favorable initial response supports an aggressive treatment approach. Long-term follow-up and further studies are needed to establish optimal treatment strategies.<\/jats:p>","DOI":"10.1007\/s12308-025-00653-7","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T07:28:49Z","timestamp":1754119729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myelomastocytic transformation in chronic myeloid leukemia blast phase: A case report"],"prefix":"10.1007","volume":"18","author":[{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feryal","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samah","family":"Kohla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Ganwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Akiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"key":"653_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1309\/AJCPWEX5YY4PHSCN","volume":"143","author":"Y Shi","year":"2015","unstructured":"Shi Y, Rand AJ, Crow JH, Moore JO, Lagoo AS (2015) Blast phase in chronic myelogenous leukemia is skewed toward unusual blast types in patients treated with tyrosine kinase inhibitors: a comparative study of 67 cases. Am J Clin Pathol 143:105\u2013119. https:\/\/doi.org\/10.1309\/AJCPWEX5YY4PHSCN","journal-title":"Am J Clin Pathol"},{"key":"653_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Kantarjian H (2022) Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol 97:1236\u20131256. https:\/\/doi.org\/10.1002\/ajh.26642","journal-title":"Am J Hematol"},{"key":"653_CR3","doi-asserted-by":"publisher","unstructured":"Deininger MW (2015) Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book 35(1):e381\u2013e388. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e381","DOI":"10.14694\/EdBook_AM.2015.35.e381"},{"key":"653_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s0145-2126(01)00040-6","volume":"25","author":"P Valent","year":"2001","unstructured":"Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny HP et al (2001) Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res 25:595\u2013602. https:\/\/doi.org\/10.1016\/s0145-2126(01)00040-6","journal-title":"Leuk Res"},{"key":"653_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2020.100222","volume":"14","author":"J Song","year":"2020","unstructured":"Song J, Liu K, Pinilla-Ibarz J, Zhang H (2020) A case report and case review: chronic myeloid leukemia (CML) blast phase with myelomastocytic differentiation. Leuk Res Rep 14:100222. https:\/\/doi.org\/10.1016\/j.lrr.2020.100222","journal-title":"Leuk Res Rep"},{"key":"653_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/ajh.21713","volume":"85","author":"AR Arredondo","year":"2010","unstructured":"Arredondo AR, Gotlib J, Shier L, Medeiros B, Wong K, Cherry A et al (2010) Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol 85:600\u2013606. https:\/\/doi.org\/10.1002\/ajh.21713","journal-title":"Am J Hematol"},{"key":"653_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1586\/17474086.2014.942280","volume":"7","author":"H-P Horny","year":"2014","unstructured":"Horny H-P, Sotlar K, Reiter A, Valent P (2014) Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis. Expert Rev Hematol 7:431\u2013437. https:\/\/doi.org\/10.1586\/17474086.2014.942280","journal-title":"Expert Rev Hematol"},{"key":"653_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/sj.thj.6200164","volume":"3","author":"P Valent","year":"2002","unstructured":"Valent P, Samorapoompichit P, Sperr WR, Horny H-P, Lechner K (2002) Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 3:90\u201394. https:\/\/doi.org\/10.1038\/sj.thj.6200164","journal-title":"Hematol J"},{"key":"653_CR9","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/j.clml.2014.06.003","volume":"14","author":"A Rich","year":"2014","unstructured":"Rich A, Sun J, Aldayel AS, Yin CC, Medeiros LJ, Konoplev S (2014) Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature. Clin Lymphoma Myeloma Leuk 14:e173-177. https:\/\/doi.org\/10.1016\/j.clml.2014.06.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"653_CR10","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1200\/JCO.2010.34.1610","volume":"29","author":"CE Vigil","year":"2011","unstructured":"Vigil CE, Wang SA, Cortes JE, Bueso-Ramos C, Verstovsek S, Shinder R et al (2011) Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase. J Clin Oncol 29:e514-516. https:\/\/doi.org\/10.1200\/JCO.2010.34.1610","journal-title":"J Clin Oncol"},{"key":"653_CR11","doi-asserted-by":"publisher","unstructured":"Martinez-Cordero H, Pati\u00f1o-Escobar B, Enciso LJ, Otero DM, Spirko P (2019) Myelomastocytic blast cell crisis in resistant tyrosine kinase inhibitor chronic myelogenous leukemia: case report and review of literature. Cureus 11:4703. https:\/\/doi.org\/10.7759\/cureus.4703.","DOI":"10.7759\/cureus.4703"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-025-00653-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-025-00653-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T04:09:28Z","timestamp":1754366968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-025-00653-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s12308-025-00653-7","relation":{},"ISSN":["1868-9256","1865-5785"],"issn-type":[{"value":"1868-9256","type":"print"},{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"8 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report was approved by the Hamad Medical Corporation\u2019s Medical Research Center. Written informed consent was obtained from the patient for publication of the details of his medical case and accompanying images.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The consent is uploaded to our research center website.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The consent is uploaded to our research center website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"38"}}